Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 20,356 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 20,356 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $31.11, for a total value of $633,275.16. Following the sale, the insider owned 21,479 shares in the company, valued at approximately $668,211.69. This represents a 48.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

CSTL opened at $30.47 on Friday. The business has a 50 day moving average of $23.55 and a 200-day moving average of $26.16. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The stock has a market cap of $930.86 million, a price-to-earnings ratio of -46.17 and a beta of 0.98. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. On average, equities research analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CSTL. KeyCorp set a $35.00 price target on Castle Biosciences in a report on Friday, May 29th. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Roth Capital started coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, BTIG Research increased their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Institutional Investors Weigh In On Castle Biosciences

Several large investors have recently added to or reduced their stakes in CSTL. Global Retirement Partners LLC acquired a new position in Castle Biosciences in the second quarter valued at approximately $26,000. Federated Hermes Inc. bought a new stake in shares of Castle Biosciences in the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Castle Biosciences during the 4th quarter valued at $35,000. Jones Financial Companies Lllp lifted its position in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after acquiring an additional 297 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
• Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
• Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.